SFG
CPRX

Steward Financial Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Steward Financial Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$0 Buy
+5
New +$67 ﹤0.01% 1367
2023
Q2 		– Sell
-7
Closed – – 578
2023
Q1 		$0 Buy
+7
New +$115 ﹤0.01% 759

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Steward Financial Group's CPRX Position: Q3 2023 in Review

Steward Financial Group opened a new position in Catalyst Pharmaceutical (CPRX) in Q3 2023: 5 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1367 among its holdings. This is a return to the name: Steward Financial Group previously reported a position in CPRX as recently as Q1 2023.

Steward Financial Group first reported a position in CPRX in Q1 2023 and has held it in 2 quarters since. 255 funds tracked by Wall St. Rank hold CPRX as of Q3 2023.

  • Steward Financial Group held 5 shares of Catalyst Pharmaceutical worth $0 as of Q3 2023.
  • Catalyst Pharmaceutical was a new Steward Financial Group position in Q3 2023.
  • Catalyst Pharmaceutical made up ﹤0.01% of Steward Financial Group's portfolio in Q3 2023, its #1367 holding.
  • Steward Financial Group first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 2 quarters since.
  • 255 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2023.

Based on Steward Financial Group's 13F filing for Q3 2023, filed 23 Oct 2023.